Role of the plasma membrane transporter of organic cations OCT1 and its genetic variants in modern liver pharmacology

BioMed Research International

Volumn 2013, Issue , 2013, Pages

  Lozano, Elisa ^a   Herraez, Elisa ^a   Briz, Oscar ^a,b   Robledo, Virginia S ^a   Hernandez Iglesias, Jorge ^a   Gonzalez Hernandez, Ana ^a   Marin, Jose J G ^a,b  

^a UNIVERSITY OF SALAMANCA   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

LAMIVUDINE; LEVODOPA; METFORMIN; ONDANSETRON; ORGANIC ANION TRANSPORTER 1; SORAFENIB; TROPISETRON; ORGANIC CATION TRANSPORTER 1;

ALTERNATIVE RNA SPLICING; ARTICLE; CANCER CELL; CELL MEMBRANE TRANSPORT; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DETOXIFICATION; DRUG EFFICACY; DRUG METABOLISM; DRUG RESPONSE; DRUG TRANSPORT; ENZYME SPECIFICITY; EXON SKIPPING; GENETIC VARIABILITY; GLYCOSYLATION; HUMAN; INTRON RETENTION; LIVER CANCER; LIVER CELL; LIVER METABOLISM; MISSENSE MUTATION; NONHUMAN; NONSENSE MUTATION; NUCLEOTIDE SEQUENCE; PH; PROMOTER REGION; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTON TRANSPORT; SINGLE NUCLEOTIDE POLYMORPHISM; TARGET ORGAN; TISSUE DISTRIBUTION; CELL MEMBRANE; CHEMISTRY; GENETICS; LIVER; METABOLISM; PATHOLOGY; REVIEW; TRANSPORT AT THE CELLULAR LEVEL;

BIOLOGICAL TRANSPORT; CELL MEMBRANE; GENETIC VARIATION; HUMANS; LIVER; ORGANIC CATION TRANSPORTER 1; TISSUE DISTRIBUTION;

EID: 84883167778     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2013/692071     Document Type: Article

References (113)

1. Bruix J., Raoul J. L., Sherman M., Mazzaferro V., Bolondi L., Craxi A., Galle P. R., Santoro A., Beaugrand M., Sangiovanni A., Porta C., Gerken G., Marrero J. A., Nadel A., Shan M., Moscovici M., Voliotis D., Llovet J. M., Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. Journal of Hepatology 2012 57 821 829
2. Martinez-Becerra P., Vaquero J., Romero M. R., Lozano E., Anadon C., Macias R. I., Serrano M. A., Grane-Boladeras N., Munoz-Bellvis L., Alvarez L., Sangro B., Pastor-Anglada M., Marin J. J., No correlation between the expression of FXR and genes involved in multidrug resistance phenotype of primary liver tumors. Molecular Pharmacology 2012 9 1693 1704
3. Herraez E., Lozano E., Macias R. I., Vaquero J., Bujanda L., Banales J. M., Marin J. J., Briz O., The expression of SLC22A1 variants may affect the response of hepatocellular carcinoma and cholangiocarcinoma to sorafenib. Hepatology 2013 10.1002/hep.26425
4. Minematsu T., Giacomini K. M., Interactions of tyrosine kinase inhibitors with organic cation transporters and multidrug and toxic compound extrusion proteins. Molecular Cancer Therapeutics 2011 10 3 531 539 2-s2.0-79955092770 10.1158/1535-7163.MCT-10-0731
5. Shikata E., Yamamoto R., Takane H., Shigemasa C., Ikeda T., Otsubo K., Ieiri I., Human organic cation transporter (OCT1 and OCT2) gene polymorphisms and therapeutic effects of metformin. Journal of Human Genetics 2007 52 2 117 122 2-s2.0-33846617263 10.1007/s10038-006-0087-0
6. Zhang S., Lovejoy K. S., Shima J. E., Lagpacan L. L., Shu Y., Lapuk A., Chen Y., Komori T., Gray J. W., Chen X., Lippard S. J., Giacomini K. M., Organic cation transporters are determinants of oxaliplatin cytotoxicity. Cancer Research 2006 66 17 8847 8857 2-s2.0-33749037182 10.1158/0008-5472.CAN-06-0769
7. Koepsell H., Lips K., Volk C., Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications. Pharmaceutical Research 2007 24 7 1227 1251 2-s2.0-34249943356 10.1007/s11095-007-9254-z
8. Meijer D. K., Mol W. E., Müller M., Kurz G., Carrier-mediated transport in the hepatic distribution and elimination of drugs, with special reference to the category of organic cations. Journal of Pharmacokinetics and Biopharmaceutics 1990 18 1 35 70 2-s2.0-0025281139 10.1007/BF01063621
9. Schmitt B. M., Koepsell H., Alkali cation binding and permeation in the rat organic cation transporter rOCT2. Journal of Biological Chemistry 2005 280 26 24481 24490 2-s2.0-21644488840 10.1074/jbc.M414550200
10. van Montfoort J. E., Müller M., Groothuis G. M. M., Meijer D. K. F., Koepsell H., Meier P. J., Comparison of "type I" and "type II" organic cation transport by organic cation transporters and organic anion-transporting polypeptides. Journal of Pharmacology and Experimental Therapeutics 2001 298 1 110 115 2-s2.0-0034968246
11. Koepsell H., Endou H., The SLC22 drug transporter family. Pflugers Archiv 2004 447 5 666 676 2-s2.0-1242295185 10.1007/s00424-003-1089-9
12. Koepsell H., The SLC22 family with transporters of organic cations, anions and zwitterions. Molecular Aspects of Medicine 2013 34 413 435
13. Gründemann D., Gorboulev V., Gambaryan S., Veyhl M., Koepsell H., Drug excretion mediated by a new prototype of polyspecific transporter. Nature 1994 372 6506 549 552 2-s2.0-0028063302 10.1038/372549a0
14. Zhang L., Dresser M. J., Gray A. T., Yost S. C., Terashita S., Giacomini K. M., Cloning and functional expression of a human liver organic cation transporter. Molecular Pharmacology 1997 51 6 913 921 2-s2.0-0030915085
15. Green R. M., Lo K., Sterritt C., Beier D. R., Cloning and functional expression of a mouse liver organic cation transporter. Hepatology 1999 29 5 1556 1562 2-s2.0-0032900120 10.1002/hep.510290530
16. Koehler M. R., Wissinger B., Gorboulev V., Koepsell H., Schmid M., The two human organic cation transporter genes SLC22A1 and SLC22A2 are located on chromosome 6q26. Cytogenetics and Cell Genetics 1997 79 3-4 198 200 2-s2.0-0031410948
17. Gründemann D., Schömig E., Gene structures of the human non-neuronal monoamine transporters EMT and OCT2. Human Genetics 2000 106 6 627 635 2-s2.0-18844465361 10.1007/s004390050035
18. Hayer M., Bönisch H., Brüss M., Molecular cloning, functional characterization and genomic organization of four alternatively spliced isoforms of the human organic cation transporter 1 (hOCT1/SLC22A1). Annals of Human Genetics 1999 63 6 473 482 2-s2.0-0342699762 10.1017/S0003480099007770
19. Wright S. H., Role of organic cation transporters in the renal handling of therapeutic agents and xenobiotics. Toxicology and Applied Pharmacology 2005 204 3 309 319 2-s2.0-17444421115 10.1016/j.taap.2004.10.021
20. Burckhardt G., Wolff N. A., Structure of renal organic anion and cation transporters. American Journal of Physiology 2000 278 6 F853 F866 2-s2.0-0033921479
21. Eraly S. A., Bush K. T., Sampogna R. V., Bhatnagar V., Nigam S. K., The molecular pharmacology of organic anion transporters: from DNA to FDA? Molecular Pharmacology 2004 65 3 479 487 2-s2.0-1342287145 10.1124/mol.65.3.479
22. Popp C., Gorboulev V., Müller T. D., Gorbunov D., Shatskaya N., Koepsell H., Amino acids critical for substrate affinity of rat organic cation transporter 1 line the substrate binding region in a model derived from the tertiary structure of lactose permease. Molecular Pharmacology 2005 67 5 1600 1611 2-s2.0-17644411713 10.1124/mol.104.008839
23. Koepsell H., Substrate recognition and translocation by polyspecific organic cation transporters. Biological Chemistry 2011 392 1-2 95 101 2-s2.0-78651362677 10.1515/BC.2011.009
24. Marin J. J. G., Briz O., Monte M. J., Blazquez A. G., Macias R. I. R., Genetic variants in genes involved in mechanisms of chemoresistance to anticancer drugs. Current Cancer Drug Targets 2012 12 4 402 438 2-s2.0-84860282454 10.2174/156800912800190875
25. Leabman M. K., Huang C. C., DeYoung J., Carlson E. J., Taylor T. R., De la Cruz M., Johns S. J., Stryke D., Kawamoto M., Urban T. J., Kroetz D. L., Ferrin T. E., Clark A. G., Risch N., Herskowitz I., Giacomini K. M., Altman R. B., Benet L. Z., Brett C. M., Burchard E. G., Castro R., Edwards R. H., Gitschier J., Glatt C. E., Ho C., Klein T., Lin E. T., Reus V. I., Sadee W., Salazar M., Schaefer C., Sheiner L. B., Tran C., Vulpe C., Wright E. M., Natural variation in human membrane transporter genes reveals evolutionary and functional constraints. Proceedings of the National Academy of Sciences of the United States of America 2003 100 10 5896 5901 2-s2.0-0038612980 10.1073/pnas.0730857100
26. Kerb R., Brinkmann U., Chatskaia N., Gorbunov D., Gorboulev V., Mornhinweg E., Keil A., Eichelbaum M., Koepsell H., Identification of genetic variations of the human organic cation transporter hOCT1 and their functional consequences. Pharmacogenetics 2002 12 8 591 595 2-s2.0-0036865724 10.1097/00008571-200211000-00002
27. Saito S., Iida A., Sekine A., Ogawa C., Kawauchi S., Higuchi S., Nakamura Y., Catalog of 238 variations among six human genes encoding solute carriers (hSLCs) in the Japanese population. Journal of Human Genetics 2002 47 11 576 584 2-s2.0-0036952563
28. Itoda M., Saito Y., Maekawa K., Hichiya H., Komamura K., Kamakura S., Kitakaze M., Tomoike H., Ueno K., Ozawa S., Sawada J.-I., Seven novel single nucleotide polymorphisms in the human SLC22A1 gene encoding organic cation transporter 1 (OCT1). Drug Metabolism and Pharmacokinetics 2004 19 4 308 312 2-s2.0-16644372503
29. Tarasova L., Kalnina I., Geldnere K., Bumbure A., Ritenberga R., Nikitina-Zake L., Fridmanis D., Vaivade I., Pirags V., Klovins J., Association of genetic variation in the organic cation transporters OCT1, OCT2 and multidrug and toxin extrusion 1 transporter protein genes with the gastrointestinal side effects and lower BMI in metformin-treated type 2 diabetes patients. Pharmacogenetics and Genomics 2012 22 659 666
30. Shu Y., Leabman M. K., Feng B., Mangravite L. M., Huang C. C., Stryke D., Kawamoto M., Johns S. J., DeYoung J., Carlson E., Ferrin T. E., Herskowitz I., Giacomini K. M., Benet L. Z., Brett C. M., Burchard E. G., Castro R., De la Cruz M., Edwards R. H., Gitschier J., Glatt C. E., Ho C., Kroetz D. L., Lin E. T., Reus V. I., Sadee W., Salazar M., Schaefer C., Sheiner L. B., Tran C., Urban T. J., Vulpe C., Wright E. M., Evolutionary conservation predicts function of variants of the human organic cation transporter, OCT1. Proceedings of the National Academy of Sciences of the United States of America 2003 100 10 5902 5907 2-s2.0-0038184179 10.1073/pnas.0730858100
31. Dong H. K., Sriharsha L., Xu W., Kamel-Reid S., Liu X., Siminovitch K., Messner H. A., Lipton J. H., Clinical relevance of a pharmacogenetic approach using multiple candidate genes to predict response and resistance to imatinib therapy in chronic myeloid leukemia. Clinical Cancer Research 2009 15 14 4750 4758 2-s2.0-68049087941 10.1158/1078-0432.CCR-09-0145
32. Takeuchi A., Motohashi H., Okuda M., Inui K., Decreased function of genetic variants, Pro283Leu and Arg287Gly, in human organic cation transporter hOCT1. Drug Metabolism and Pharmacokinetics 2003 18 409 412
33. Sakata T., Anzai N., Shin H. J., Noshiro R., Hirata T., Yokoyama H., Kanai Y., Endou H., Novel single nucleotide polymorphisms of organic cation transporter 1 (SLC22A1) affecting transport functions. Biochemical and Biophysical Research Communications 2004 313 3 789 793 2-s2.0-0347859200 10.1016/j.bbrc.2003.11.175
34. Nies A. T., Koepsell H., Winter S., Burk O., Klein K., Kerb R., Zanger U. M., Keppler D., Schwab M., Schaeffeler E., Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver. Hepatology 2009 50 4 1227 1240 2-s2.0-70350075408 10.1002/hep.23103
35. Chen L., Takizawa M., Chen E., Schlessinger A., Segenthelar J., Choi J. H., Sali A., Kubo M., Nakamura S., Iwamoto Y., Iwasaki N., Giacomini K. M., Genetic polymorphisms in organic cation transporter 1 (OCT1) in Chinese and Japanese populations exhibit altered function. Journal of Pharmacology and Experimental Therapeutics 2010 335 1 42 50 2-s2.0-77957238214 10.1124/jpet.110.170159
36. Shu Y., Sheardown S. A., Brown C., Owen R. P., Zhang S., Castro R. A., Ianculescu A. G., Yue L., Lo J. C., Burchard E. G., Brett C. M., Giacomini K. M., Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. Journal of Clinical Investigation 2007 117 5 1422 1431 2-s2.0-34248156160 10.1172/JCI30558
37. Langston J. W., Ballard P., Tetrud J. W., Irwin I., Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 1983 219 4587 979 980 2-s2.0-0020680904
38. Yang M. C., McLean A. J., Le Couteur D. G., Cell membrane transport of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)in the liver and systemic bioavailability. Biochemical and Biophysical Research Communications 2001 289 1 130 136 2-s2.0-0035940980 10.1006/bbrc.2001.5954
39. Becker M. L., Visser L. E., van Schaik R. H. N., Hofman A., Uitterlinden A. G., Stricker B. H. C., Genetic variation in the organic cation transporter 1 is associated with metformin response in patients with diabetes mellitus. Pharmacogenomics Journal 2009 9 4 242 247 2-s2.0-67849116869 10.1038/tpj.2009.15
40. Becker M. L., Visser L. E., van Schaik R. H. N., Hofman A., Uitterlinden A. G., Stricker B. H. C., OCT1 polymorphism is associated with response and survival time in anti-Parkinsonian drug users. Neurogenetics 2011 12 1 79 82 2-s2.0-79951554624 10.1007/s10048-010-0254-5
41. Choi M.-K., Song I.-S., Genetic variants of organic cation transporter 1 (OCT1) and OCT2 significantly reduce lamivudine uptake. Biopharmaceutics and Drug Disposition 2012 33 3 170 178 2-s2.0-84859719229 10.1002/bdd.1783
42. Li S., Chen Y., Zhang S., More S. S., Huang X., Giacomini K. M., Role of organic cation transporter 1, OCT1 in the pharmacokinetics and toxicity of cis-diammine(pyridine)chloroplatinum(II) and oxaliplatin in mice. Pharmaceutical Research 2011 28 3 610 625 2-s2.0-79952485264 10.1007/s11095-010-0312-6
43. Tzvetkov M. V., Saadatmand A. R., Bokelmann K., Meineke I., Kaiser R., Brockmöller J., Effects of OCT1 polymorphisms on the cellular uptake, plasma concentrations and efficacy of the 5-HT 3 antagonists tropisetron and ondansetron. Pharmacogenomics Journal 2012 12 1 22 29 2-s2.0-84856233573 10.1038/tpj.2010.75
44. Jonker J. W., Schinkel A. H., Pharmacological and physiological functions of the polyspecific organic cation transporters: OCT1, 2, and 3 (SLC22A1-3). Journal of Pharmacology and Experimental Therapeutics 2004 308 1 2 9 2-s2.0-0345866860 10.1124/jpet.103.053298
45. Wang D.-S., Jonker J. W., Kato Y., Kusuhara H., Schinkel A. H., Sugiyama Y., Involvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin. Journal of Pharmacology and Experimental Therapeutics 2002 302 2 510 515 2-s2.0-0036070666 10.1124/jpet.102.034140
46. Crossman L. C., Druker B. J., Deininger M. W. N., Pirmohamed M., Wang L., Clark R. E., hOCT 1 and resistance to imatinib. Blood 2005 106 3 1133 1134 2-s2.0-23044433630 10.1182/blood-2005-02-0694
47. Wang L., Giannoudis A., Lane S., Williamson P., Pirmohamed M., Clark R. E., Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia. Clinical Pharmacology and Therapeutics 2008 83 2 258 264 2-s2.0-38349193809 10.1038/sj.clpt.6100268
48. Nardinelli L., Sanabani S. S., Didone A., Ferreira P. D. B., Serpa M., Novaes M. M. Y., Marchiani M., Ruiz A. L., Lima I. S., Chamone D. D. A. F., Bendit I., Pretherapeutic expression of the hOCT1 gene predicts a complete molecular response to imatinib mesylate in chronic-phase chronic myeloid leukemia. Acta Haematologica 2012 127 4 228 234 2-s2.0-84859649735 10.1159/000336610
49. Giannoudis A., Wang L., Jorgensen A. L., Xinarianos G., Davies A., Pushpakom S., Liloglou T., Zhang J. E., Austin G., Holyoake T. L., Foroni L., Kottaridis P. D., Muller M. C., Pirmohamed M., Clark R. E., The hOCT1 SNPs M420del and M408V alter imatinib uptake and M420del modifies clinical outcome in imatinib-treated chronic myeloid leukemia. Blood 2013 121 628 637
50. Gorboulev V., Ulzheimer J. C., Akhoundova A., Ulzheimer-Teuber I., Karbach U., Quester S., Baumann C., Lang F., Busch A. E., Koepsell H., Cloning and characterization of two human polyspecific organic cation transporters. DNA and Cell Biology 1997 16 7 871 881
51. Meyer-Wentrup F., Karbach U., Gorboulev V., Arndt P., Koepsell H., Membrane localization of the electrogenic cation transporter rOCT1 in rat liver. Biochemical and Biophysical Research Communications 1998 248 3 673 678 2-s2.0-0032581363 10.1006/bbrc.1998.9034
52. Lautem A., Heise M., Grasel A., Hoppe-Lotichius M., Weiler N., Foltys D., Knapstein J., Schattenberg J. M., Schad A., Zimmermann A., Otto G., Lang H., Galle P. R., Schuchmann M., Zimmermann T., Downregulation of organic cation transporter 1 (SLC22A1) is associated with tumor progression and reduced patient survival in human cholangiocellular carcinoma. International Journal of Oncology 2013 42 4 1297 1304 10.3892/ijo.2013.1840
53. Verhaagh S., Schweifer N., Barlow D. P., Zwart R., Cloning of the mouse and human solute carrier 22a3 (Slc22a3/SLC22A3) identifies a conserved cluster of three organic cation transporters on mouse chromosome 17 and human 6q26-q27. Genomics 1999 55 2 209 218 2-s2.0-0033555592 10.1006/geno.1998.5639
54. Busch A. E., Karbach U., Miska D., Gorboulev V., Akhoundova A., Volk C., Arndt P., Ulzheimer J. C., Sonders M. S., Baumann C., Waldegger S., Lang F., Koepsell H., Human neurons express the polyspecific cation transporter hOCT2, which translocates monoamine neurotransmitters, amantadine, and memantine. Molecular Pharmacology 1998 54 2 342 352 2-s2.0-0031824347
55. Dresser M. J., Gray A. T., Giacomini K. M., Kinetic and selectivity differences between rodent, rabbit, and human organic cation transporters (OCT1). Journal of Pharmacology and Experimental Therapeutics 2000 292 3 1146 1152 2-s2.0-0034010850
56. Mehrens T., Lelleck S., Çetinkaya I., Knollmann M., Hohage H., Gorboulev V., Bokník P., Koepsell H., Schlatter E., The affinity of the organic cation transporter rOCT1 is increased by protein kinase C-dependent phosphorylation. Journal of the American Society of Nephrology 2000 11 7 1216 1224 2-s2.0-0034081998
57. Schlatter E., Mönnich V., Çetinkaya I., Mehrens T., Ciarimboli G., Hirsch J. R., Popp C., Koepsell H., The organic cation transporters rOCT1 and hOCT2 are inhibited by cGMP. Journal of Membrane Biology 2002 189 3 237 244 2-s2.0-0036782039 10.1007/s00232-002-1023-7
58. Nies A. T., Herrmann E., Brom M., Keppler D., Vectorial transport of the plant alkaloid berberine by double-transfected cells expressing the human organic cation transporter 1 (OCT1, SLC22A1) and the efflux pump MDR1 P-glycoprotein (ABCB1). Naunyn-Schmiedeberg's Archives of Pharmacology 2008 376 6 449 461 2-s2.0-38349168958 10.1007/s00210-007-0219-x
59. Moon K. K., Shim C.-K., The transport of organic cations in the small intestine: current knowledge and emerging concepts. Archives of Pharmacal Research 2006 29 7 605 616 2-s2.0-33746887344
60. Yasujima T., Ohta K., Inoue K., Yuasa H., Characterization of human OCT1-mediated transport of DAPI as a fluorescent probe substrate. Journal of Pharmaceutical Sciences 2011 100 9 4006 4012 2-s2.0-79960120117 10.1002/jps.22548
61. Ahlin G., Karlsson J., Pedersen J. M., Gustavsson L., Larsson R., Matsson P., Norinder U., Bergström C. A. S., Artursson P., Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1. Journal of Medicinal Chemistry 2008 51 19 5932 5942 2-s2.0-53549119190 10.1021/jm8003152
62. Bednarczyk D., Mash E. A., Aavula B. R., Wright S. H., NBD-TMA: a novel fluorescent substrate of the peritubular organic cation transporter of renal proximal tubules. Pflugers Archiv 2000 440 1 184 192 2-s2.0-0034026485 10.1007/s004240051038
63. Lee W.-K., Wolff N. A., Thévenod F., Organic cation transporters: physiology, toxicology and special focus on ethidium as a novel substrate. Current Drug Metabolism 2009 10 6 617 631 2-s2.0-70450121903 10.2174/138920009789375360
64. Chen Y., Zhang S., Sorani M., Giacomini K. M., Transport of paraquat by human organic cation transporters and multidrug and toxic compound extrusion family. Journal of Pharmacology and Experimental Therapeutics 2007 322 2 695 700 2-s2.0-34547103001 10.1124/jpet.107.123554
65. Kimura N., Masuda S., Katsura T., Inui K.-I., Transport of guanidine compounds by human organic cation transporters, hOCT1 and hOCT2. Biochemical Pharmacology 2009 77 8 1429 1436 2-s2.0-62549101989 10.1016/j.bcp.2009.01.010
66. Tachampa K., Takeda M., Khamdang S., Noshiro-Kofuji R., Tsuda M., Jariyawat S., Fukutomi T., Sophasan S., Anzai N., Endou H., Interactions of organic anion transporters and organic cation transporters with mycotoxins. Journal of Pharmacological Sciences 2008 106 3 435 443 2-s2.0-41549138734 10.1254/jphs.FP0070911
67. Koepsell H., Polyspecific organic cation transporters: their functions and interactions with drugs. Trends in Pharmacological Sciences 2004 25 7 375 381 2-s2.0-3042569768 10.1016/j.tips.2004.05.005
68. Sala-Rabanal M., Li D. C., Dake G. R., Kurata H. T., Inyushin M., Skatchkov S. N., Nichols C. G., Polyamine transport by the polyspecific organic cation transporters OCT1, OCT2, and OCT3. Molecular Pharmaceutics 2013 10 1450 1458
69. Gründemann D., Hahne C., Berkels R., Schömig E., Agmatine is efficiently transported by non-neuronal monoamine transporters extraneuronal monoamine transporter (EMT) and organic cation transporter 2 (OCT2). Journal of Pharmacology and Experimental Therapeutics 2003 304 2 810 817 2-s2.0-0037309520 10.1124/jpet.102.044404
70. Kimura H., Takeda M., Narikawa S., Enomoto A., Ichida K., Endou H., Human organic anion transporters and human organic cation transporters mediate renal transport of prostaglandins. Journal of Pharmacology and Experimental Therapeutics 2002 301 1 293 298 2-s2.0-0036198625 10.1124/jpet.301.1.293
71. Lemos C., Faria A., Meireles M., Martel F., Monteiro R., Calhau C., Thiamine is a substrate of organic cation transporters in Caco-2 cells. European Journal of Pharmacology 2012 682 1-3 37 42 2-s2.0-84859099760 10.1016/j.ejphar.2012.02.028
72. +/organic cation antiporter, kidney-specific multidrug and toxin extrusion 2. Journal of the American Society of Nephrology 2006 17 8 2127 2135 2-s2.0-33746548445 10.1681/ASN.2006030205
73. de Deyn P., Marescau B., Lornoy W., Becaus I., Lowenthal A., Guanidino compounds in uraemic dialysed patients. Clinica Chimica Acta 1986 157 2 143 150 2-s2.0-0022504842
74. Kishore B. K., Kallay Z., Tulkens P. M., Clinico-biochemical aspects of guanidine compounds in uraemic toxicity. International Urology and Nephrology 1989 21 2 223 232 2-s2.0-0024560177
75. Harlfinger S., Fork C., Lazar A., Schömig E., Gründemann D., Are organic cation transporters capable of transporting prostaglandins? Naunyn-Schmiedeberg's Archives of Pharmacology 2005 372 2 125 130 2-s2.0-27144542651 10.1007/s00210-005-0011-8
76. Hayer-Zillgen M., Brüss M., Bönisch H., Expression and pharmacological profile of the human organic cation transporters hOCT1, hOCT2 and hOCT3. British Journal of Pharmacology 2002 136 6 829 836 2-s2.0-0036022593 10.1038/sj.bjp.0704785
77. Schaeffeler E., Hellerbrand C., Nies A. T., Winter S., Kruck S., Hofmann U., van der Kuip H., Zanger U. M., Koepsell H., Schwab M., DNA methylation is associated with downregulation of the organic cation transporter OCT1 (SLC22A1) in human hepatocellular carcinoma. Genome Medicine 2011 3 12, article 82 2-s2.0-84155173299 10.1186/gm298
78. Casero R. A. Jr., Pegg A. E., Polyamine catabolism and disease. Biochemical Journal 2009 421 3 323 338 2-s2.0-69249245459 10.1042/BJ20090598
79. Zhang L., Schaner M. E., Giacomini K. M., Functional characterization of an organic cation transporter (hOCT1) in a transiently transfected human cell line (HeLa). Journal of Pharmacology and Experimental Therapeutics 1998 286 1 354 361 2-s2.0-0031846917
80. Gründemann D., Schechinger B., Rappold G. A., Schömig E., Molecular identification of the corticosterone-sensitive extraneuronal catecholamine transporter. Nature Neuroscience 1998 1 5 349 351 2-s2.0-0032150876
81. Müller J., Lips K. S., Metzner L., Neubert R. H. H., Koepsell H., Brandsch M., Drug specificity and intestinal membrane localization of human organic cation transporters (OCT). Biochemical Pharmacology 2005 70 12 1851 1860 2-s2.0-27744454598 10.1016/j.bcp.2005.09.011
82. Ciarimboli G., Schlatter E., Regulation of organic cation transport. Pflugers Archiv 2005 449 5 423 441 2-s2.0-13744263546 10.1007/s00424-004-1355-5
83. Ciarimboli G., Struwe K., Arndt P., Gorboulev V., Koepsell H., Schlatter E., Hirsch J. R., Regulation of the human organic cation transporter hOCT1. Journal of Cellular Physiology 2004 201 3 420 428 2-s2.0-7644239482 10.1002/jcp.20081
84. Martel F., Keating E., Calhau C., Gründemann D., Schömig E., Azevedo I., Regulation of human extraneuronal monoamine transporter (hEMT) expressed in HEK293 cells by intracellular second messenger systems. Naunyn-Schmiedeberg's Archives of Pharmacology 2001 364 6 487 495 2-s2.0-0035206702 10.1007/s002100100476
85. Ciarimboli G., Koepsell H., Iordanova M., Gorboulev V., Dürner B., Lang D., Edemir B., Schröter R., Van Le T., Schlatter E., Individual PKC-phosphorylation sites in organic cation transporter 1 determine substrate selectivity and transport regulation. Journal of the American Society of Nephrology 2005 16 6 1562 1570 2-s2.0-26944460462 10.1681/ASN.2004040256
86. Saborowski M., Kullak-Ublick G. A., Eloranta J. J., The human organic cation transporter-1 gene is transactivated by hepatocyte nuclear factor-4 α Journal of Pharmacology and Experimental Therapeutics 2006 317 2 778 785 2-s2.0-33645870991 10.1124/jpet.105.099929
87. Heise M., Lautem A., Knapstein J., Schattenberg J. M., Hoppe-Lotichius M., Foltys D., Weiler N., Zimmermann A., Schad A., Gründemann D., Otto G., Galle P. R., Schuchmann M., Zimmermann T., Downregulation of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) in human hepatocellular carcinoma and their prognostic significance. BMC Cancer 2012 12 article 109 2-s2.0-84858713948 10.1186/1471-2407-12-109
88. Tzvetkov M. V., Saadatmand A. R., Lötsch J., Tegeder I., Stingl J. C., Brockmöller J., Genetically polymorphic OCT1: another piece in the puzzle of the variable pharmacokinetics and pharmacodynamics of the opioidergic drug tramadol. Clinical Pharmacology and Therapeutics 2011 90 1 143 150 2-s2.0-79959375990 10.1038/clpt.2011.56
89. Dickens D., Owen A., Alfirevic A., Giannoudis A., Davies A., Weksler B., Romero I. A., Couraud P.-O., Pirmohamed M., Lamotrigine is a substrate for OCT1 in brain endothelial cells. Biochemical Pharmacology 2012 83 6 805 814 2-s2.0-84857062912 10.1016/j.bcp.2011.12.032
90. Watanabe K., Sawano T., Endo T., Sakata M., Sato J., Studies on intestinal absorption of sulpiride (2): transepithelial transport of sulpiride across the human intestinal cell line Caco-2. Biological and Pharmaceutical Bulletin 2002 25 10 1345 1350 2-s2.0-0036781112 10.1248/bpb.25.1345
91. Umehara K.-I., Iwatsubo T., Noguchi K., Kamimura H., Functional involvement of organic cation transporter1 (OCT1/Oct1) in the hepatic uptake of organic cations in humans and rats. Xenobiotica 2007 37 8 818 831 2-s2.0-34547946755 10.1080/00498250701546012
92. Ciarimboli G., Schroter R., Neugebauer U., Vollenbroker B., Gabriels G., Brzica H., Sabolic I., Pietig G., Pavenstadt H., Schlatter E., Edemir B., Kidney transplantation down-regulates expression of organic cation transporters, which translocate beta-blockers and fluoroquinolones. Molecular Pharmacology 2013 10 2370 2380
93. Mulgaonkar A., Venitz J., Grundemann D., Sweet D. H., Human organic cation transporters 1 (SLC22A1), 2 (SLC22A2), and 3 (SLC22A3) as disposition pathways for fluoroquinolone antimicrobials. Antimicrobial Agents and Chemotherapy 2013 57 6 2705 2711
94. Gupta S., Wulf G., Henjakovic M., Koepsell H., Burckhardt G., Hagos Y., Human organic cation transporter 1 is expressed in lymphoma cells and increases susceptibility to irinotecan and paclitaxel. Journal of Pharmacology and Experimental Therapeutics 2012 341 1 16 23 2-s2.0-84858632609 10.1124/jpet.111.190561
95. Briz O., Serrano M. A., Rebollo N., Hagenbuch B., Meier P. J., Koepsell H., Marin J. J. G., Carriers involved in targeting the cytostatic bile acid-cisplatin derivatives cis-diammine-chloro-cholylglycinate-platinum(II) and cis-diammine-bisursodeoxycholate-platinum(II) toward liver cells. Molecular Pharmacology 2002 61 4 853 860 2-s2.0-0036211864 10.1124/mol.61.4.853
96. Bayer M., Kuçi Z., Schömig E., Gründemann D., Dittmann H., Handgretinger R., Bruchelt G., Uptake of mIBG and catecholamines in noradrenaline- and organic cation transporter-expressing cells: potential use of corticosterone for a preferred uptake in neuroblastoma- and pheochromocytoma cells. Nuclear Medicine and Biology 2009 36 3 287 294 2-s2.0-62749184951 10.1016/j.nucmedbio.2008.12.010
97. Minematsu T., Iwai M., Sugimoto K., Shirai N., Nakahara T., Usui T., Kamimura H., Carrier-mediated uptake of 1 -(2-methoxyethyl)-2-methyl-4,9-dioxo- 3- (pyrazin-2-ylmethyl)-4,9-dihydro-1H-naphtho[2,3-d]imidazolium Bromide (YM155 monobromide), a novel small-molecule survivin suppressant, into human solid tumor and lymphoma cells. Drug Metabolism and Disposition 2009 37 3 619 628 2-s2.0-61449213054 10.1124/dmd.108.025254
98. Thomas J., Wang L., Clark R. E., Pirmohamed M., Active transport of imatinib into and out of cells: implications for drug resistance. Blood 2004 104 12 3739 3745 2-s2.0-9444282642 10.1182/blood-2003-12-4276
99. Schmidt-Lauber C., Harrach S., Pap T., Fischer M., Victor M., Heitzmann M., Hansen U., Fobker M., Brand S. M., Sindic A., Pavenstadt H., Edemir B., Schlatter E., Bertrand J., Ciarimboli G., Transport mechanisms and their pathology-induced regulation govern tyrosine kinase inhibitor delivery in rheumatoid arthritis. PLoS One 2012 7 e52247
100. Ming X., Ju W., Wu H., Tidwell R. R., Hall J. E., Thakker D. R., Transport of dicationic drugs pentamidine and furamidine by human organic cation transporters. Drug Metabolism and Disposition 2009 37 2 424 430 2-s2.0-59649084045 10.1124/dmd.108.024083
101. Jung N., Lehmann C., Rubbert A., Knispel M., Hartmann P., Van Lunzen J., Stellbrink H.-J., Faetkenheuer G., Taubert D., Relevance of the organic cation transporters 1 and 2 for antiretroviral drug therapy in human immunodeficiency virus infection. Drug Metabolism and Disposition 2008 36 8 1616 1623 2-s2.0-47949132723 10.1124/dmd.108.020826
102. Takeda M., Khamdang S., Narikawa S., Kimura H., Kobayashi Y., Yamamoto T., Cha S. H. O., Sekine T., Endou H., Human organic anion transporters and human organic cation transporters mediate renal antiviral transport. Journal of Pharmacology and Experimental Therapeutics 2002 300 3 918 924 2-s2.0-0036175142 10.1124/jpet.300.3.918
103. Aouida M., Leduc A., Wang H., Ramotar D., Characterization of a transport and detoxification pathway for the antitumour drug bleomycin in Saccharomyces cerevisiae. Biochemical Journal 2004 384 1 47 58 2-s2.0-9444284948 10.1042/BJ20040392
104. Koepsell H., Organic cation transporters in intestine, kidney, liver, and brain. Annual Review of Physiology 1998 60 243 266 2-s2.0-0031893146 10.1146/annurev.physiol.60.1.243
105. More S. S., Li S., Yee S. W., Chen L., Xu Z., Jablons D. M., Giacomini K. M., Organic cation transporters modulate the uptake and cytotoxicity of picoplatin, a third-generation platinum analogue. Molecular Cancer Therapeutics 2010 9 4 1058 1069 2-s2.0-77950823207 10.1158/1535-7163.MCT-09-1084
106. Marin J. J., Macias R. I., Criado J. J., Bueno A., Monte M. J., Serrano M. A., DNA interaction and cytostatic activity of the new liver organotropic complex of cisplatin with glycocholic acid: Bamet-R2. International Journal of Cancer 1998 78 346 352
107. Dominguez M. F., Macias R. I. R., Izco-Basurko I., De La Fuente A., Pascual M. J., Criado J. M., Monte M. J., Yajeya J., Marin J. J. G., Low in vivo toxicity of a novel cisplatin-ursodeoxycholic derivative (Bamet-UD2) with enhanced cytostatic activity versus liver tumors. Journal of Pharmacology and Experimental Therapeutics 2001 297 3 1106 1112 2-s2.0-0035016505
108. Hartmann J. T., Haap M., Kopp H.-G., Lipp H.-P., Tyrosine kinase inhibitors-a review on pharmacology, metabolism and side effects. Current Drug Metabolism 2009 10 5 470 481 2-s2.0-70350772288 10.2174/138920009788897975
109. Philip P. A., Mahoney M. R., Allmer C., Thomas J., Pitot H. C., Kim G., Donehower R. C., Fitch T., Picus J., Erlichman C., Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer. Journal of Clinical Oncology 2005 23 27 6657 6663 2-s2.0-27244447373 10.1200/JCO.2005.14.696
110. Matsuo M., Sakurai H., Saiki I., ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, shows antimetastatic activity using a hepatocellular carcinoma model. Molecular Cancer Therapeutics 2003 2 6 557 561 2-s2.0-0142024593
111. Wilhelm S. M., Carter C., Tang L., Wilkie D., McNabola A., Rong H., Chen C., Zhang X., Vincent P., McHugh M., Cao Y., Shujath J., Gawlak S., Eveleigh D., Rowley B., Liu L., Adnane L., Lynch M., Auclair D., Taylor I., Gedrich R., Voznesensky A., Riedl B., Post L. E., Bollag G., Trail P. A., BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Research 2004 64 19 7099 7109 2-s2.0-4944249117 10.1158/0008-5472.CAN-04-1443
112. Swift B., Nebot N., Lee J. K., Han T., Proctor W. R., Thakker D. R., Lang D., Radtke M., Gnoth M. J., Brouwer K. L., Sorafenib hepatobiliary disposition: mechanisms of hepatic uptake and disposition of generated metabolites. Drug Metabolism and Disposition 2013 41 6 1179 1186
113. Kindla J., Fromm M. F., König J., In vitro evidence for the role of OATP and OCT uptake transporters in drug-drug interactions. Expert Opinion on Drug Metabolism and Toxicology 2009 5 5 489 500 2-s2.0-67649362277 10.1517/17425250902911463